Advancing Treatment Options for Merkel Cell Carcinoma: A Review of Tumor-Targeted Therapies.

ABSTRACT: Although rare, Merkel cell carcinoma (MCC) is a highly aggressive and increasingly prevalent neuroendocrine cancer of the skin. While current interventions, including surgical resection, radiation, and immunotherapy have been employed in treating many patients, those who remain unresponsive to treatment are met with sparse alternatives and a grim prognosis. For this reason, it is of interest to expand the repertoire of available therapies for MCC patients who remain resistant to current primary interventions. Recently, our improved mechanistic understanding of aberrant cell signaling observed in both MCPyV-positive and -negative MCC has facilitated exploration into several small molecules and inhibitors, among them receptor tyrosine kinase inhibitors (TKIs) and somatostatin analogs (SSAs),

SUBMITTER: Nammour HM 

PROVIDER: S-EPMC11507330 | biostudies-literature | 2024 Oct

REPOSITORIES: biostudies-literature